ReviewCurrent oncology reports2024

First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?

Marco Airoldi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.